(RTTNews) - GH Research PLC (GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, announced ...
Hosted on MSN1mon
Why GH Research PLC (GHRS) Is Skyrocketing So Far In 2025In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 after two ...
In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other psychedelic stocks. In contrast to drugs like cocaine or marijuana, psychedelics are ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Shares of GHRS stock opened at $11.00 on Thursday. The firm’s 50-day moving average is $11.13 and its 200-day moving average is $9.18. The stock has a market cap of $572.31 million, a price-to ...
In this article, we are going to take a look at where GH Research PLC (NASDAQ:GHRS) stands against the other small cap stocks. On February 14, Stacey Sears, portfolio manager at Emerald Advisors ...
Fintel reports that on March 7, 2025, RBC Capital initiated coverage of GH Research (NasdaqGM:GHRS) with a Outperform recommendation. As of March 4, 2025, the average one-year price target for GH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results